Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD

In this episode of the Oncology Unplugged series, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, spoke with Stephen Liu, MD, a thoracic oncologist and the Head of Developmental Therapeutics at Georgetown University’s Lombardi Comprehensive Cancer Center in Washington, DC, about advancements in EGFR-mutated non–small cell lung cancer (NSCLC) and key clinical trials shaping the NSCLC treatment paradigm.

Liu emphasized the importance of identifying patients with minimal residual disease (MRD) to better tailor therapy and reduce unnecessary treatment exposure. He noted ongoing research, such as efforts to develop personalized MRD markers, but acknowledged that current technologies remain suboptimal compared with advances seen in hematologic malignancies.

The discussion also addressed emerging data from the phase 3 FLAURA2 trial (NCT04035486), which explored osimertinib (Tagrisso) combined with chemotherapy in the first-line metastatic EGFR-mutated NSCLC setting. Liu noted the improvement in progression-free survival with osimertinib plus chemotherapy vs osimertinib alone but raised questions about whether upfront combination therapy is superior to sequential treatment. He also highlighted the importance of preserving quality of life, noting that single-agent osimertinib allows patients more independence and less disruption to daily life compared with regimens requiring frequent infusions.